Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 2
2009 2
2011 1
2012 2
2013 3
2014 2
2015 2
2016 1
2017 5
2018 1
2019 5
2020 3
2021 6
2022 3
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Results by year

Filters applied: . Clear all
Page 1
Platelet Function and Turnover in Essential Thrombocythemia: A Systematic Review.
Kvernberg J, Grove EL, Ommen HB, Hvas AM. Kvernberg J, et al. Semin Thromb Hemost. 2021 Feb;47(1):90-101. doi: 10.1055/s-0040-1718873. Epub 2021 Feb 1. Semin Thromb Hemost. 2021. PMID: 33525042
Essential thrombocythemia (ET) is a myeloproliferative neoplasm characterized by increased platelet counts. ...
Essential thrombocythemia (ET) is a myeloproliferative neoplasm characterized by increased platelet counts. ...
Management of Myeloproliferative Neoplasms (MPNs).
Nurgat Z, Lawrence M. Nurgat Z, et al. J Oncol Pharm Pract. 2022 Sep;28(6):1400-1410. doi: 10.1177/10781552221082293. Epub 2022 Mar 16. J Oncol Pharm Pract. 2022. PMID: 35296179
Benefits and Risks of Antithrombotic Therapy in Essential Thrombocythemia: A Systematic Review.
Chu DK, Hillis CM, Leong DP, Anand SS, Siegal DM. Chu DK, et al. Ann Intern Med. 2017 Aug 1;167(3):170-180. doi: 10.7326/M17-0284. Epub 2017 Jun 27. Ann Intern Med. 2017. PMID: 28632284 Review.
BACKGROUND: Patients with essential thrombocythemia (ET) are at high risk for both thrombosis and hemorrhage. ...
BACKGROUND: Patients with essential thrombocythemia (ET) are at high risk for both thrombosis and hemorrhage. ...
Interferon alpha therapy in essential thrombocythemia and polycythemia vera-a systematic review and meta-analysis.
Bewersdorf JP, Giri S, Wang R, Podoltsev N, Williams RT, Tallman MS, Rampal RK, Zeidan AM, Stahl M. Bewersdorf JP, et al. Leukemia. 2021 Jun;35(6):1643-1660. doi: 10.1038/s41375-020-01020-4. Epub 2020 Sep 1. Leukemia. 2021. PMID: 32868875 Free PMC article.
Data on the efficacy and safety of interferon (IFN)-alpha for the treatment of essential thrombocythemia (ET) and polycythemia vera (PV) are inconsistent. ...
Data on the efficacy and safety of interferon (IFN)-alpha for the treatment of essential thrombocythemia (ET) and polycythemia …
Incidence of Thrombosis at Different Sites During the Follow-Up Period in Essential Thrombocythemia: A Systematic Review and Meta-Analysis.
Wang D, Yu X, Sun Y, Lv Y, Li Y, Zhao P, Niu J, Zhang Y, Chen Y, Chen K, Chen Z, Liu W, Wang M, Hu X. Wang D, et al. Clin Appl Thromb Hemost. 2023 Jan-Dec;29:10760296231181117. doi: 10.1177/10760296231181117. Clin Appl Thromb Hemost. 2023. PMID: 37350087 Free PMC article.
Thrombotic events are the most frequent manifestations of essential thrombocythemia (ET). The objective of this study is to determine the incidence of thrombosis at different sites on follow-up in patients with ET. ...
Thrombotic events are the most frequent manifestations of essential thrombocythemia (ET). The objective of this study is to de …
A systematic review of the fetal safety of interferon alpha.
Yazdani Brojeni P, Matok I, Garcia Bournissen F, Koren G. Yazdani Brojeni P, et al. Reprod Toxicol. 2012 Jun;33(3):265-8. doi: 10.1016/j.reprotox.2011.11.003. Epub 2011 Dec 19. Reprod Toxicol. 2012. PMID: 22200624 Review.
BACKGROUND: Interferon alpha (IFN) is an effective treatment for a variety of conditions including essential thrombocythemia (ET), chronic myelocytic leukemia, Hepatitis B and C. ...METHODS: Reports on the use of IFN alpha in human pregnancy and reports on essent …
BACKGROUND: Interferon alpha (IFN) is an effective treatment for a variety of conditions including essential thrombocythemia ( …
Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis.
Carobbio A, Ferrari A, Masciulli A, Ghirardi A, Barosi G, Barbui T. Carobbio A, et al. Blood Adv. 2019 Jun 11;3(11):1729-1737. doi: 10.1182/bloodadvances.2019000211. Blood Adv. 2019. PMID: 31175128 Free PMC article.
In the last years, a growing amount of evidence has been produced regarding the role of leukocytosis as a risk factor for thrombosis in patients with myeloproliferative neoplasms, predominantly in polycythemia vera (PV) and essential thrombocythemia (ET). Results fr …
In the last years, a growing amount of evidence has been produced regarding the role of leukocytosis as a risk factor for thrombosis in pati …
Clinical outcomes of interferon therapy for polycythemia vera and essential thrombocythemia: a systematic review and meta-analysis.
Gu W, Yang R, Xiao Z, Zhang L. Gu W, et al. Int J Hematol. 2021 Sep;114(3):342-354. doi: 10.1007/s12185-021-03171-1. Epub 2021 Jun 6. Int J Hematol. 2021. PMID: 34091876
Interferon therapy has been used in clinical practice for more than three decades to treat polycythemia vera (PV) and essential thrombocythemia (ET). However, there has been no systematic investigation of its expected outcomes and potential risks. ...
Interferon therapy has been used in clinical practice for more than three decades to treat polycythemia vera (PV) and essential th …
How common are myeloproliferative neoplasms? A systematic review and meta-analysis.
Titmarsh GJ, Duncombe AS, McMullin MF, O'Rorke M, Mesa R, De Vocht F, Horan S, Fritschi L, Clarke M, Anderson LA. Titmarsh GJ, et al. Am J Hematol. 2014 Jun;89(6):581-7. doi: 10.1002/ajh.23690. Am J Hematol. 2014. PMID: 24971434 Free article. Review.
Myeloproliferative neoplasms (MPNs) are a heterogeneous group of diseases including polycythemia vera (PV), essential thrombocythemia (ET), and primary(idiopathic) myelofibrosis (PMF). ...
Myeloproliferative neoplasms (MPNs) are a heterogeneous group of diseases including polycythemia vera (PV), essential thrombocythe …
Estimation of diagnosis and prognosis in ET by assessment of CALR and JAK2V617F mutations and laboratory findings: a meta-analysis.
Saki N, Shirzad R, Rahim F, Saki Malehi A. Saki N, et al. Clin Transl Oncol. 2017 Jul;19(7):874-883. doi: 10.1007/s12094-017-1618-1. Epub 2017 Feb 15. Clin Transl Oncol. 2017. PMID: 28205126 Review.
BACKGROUND: Essential thrombocythemia (ET) is a benign disease with slow progress in which thrombosis is a cause of mortality. ...In this systematic review and meta-analysis, we compared the prevalence of JAK2(V617F) and CALR mutations in ET and examined the inciden …
BACKGROUND: Essential thrombocythemia (ET) is a benign disease with slow progress in which thrombosis is a cause of mortality. …
34 results